openPR Logo
Press release

Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022

07-11-2017 11:14 AM CET | Health & Medicine

Press release from: Kuick Resarch

Biosimilar Insulin Market Biosimilar Insulin Clinical

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Report Table of Contents

Prologue to Insulin Biosimilars
1.1 Outline Towards Insulin
1.2 Trail of Insulin Evolution and Development

Rationale Design of Insulin Molecule
2.1 Structure of Insulin Polypeptide
2.2 Biosynthesis of Insulin
2.3 Secretion of Insulin

Mechanism of Insulin in Diabetics
3.1 Glucose Metabolism of Insulin
3.2 Impact of Insulin Dysregulation in Diabetes 1
3.3 Impact of Insulin Resistance in Diabetes 2

Engineering of Synthetic Insulin
4.1 Production of Human Insulin
4.2 Categorization of Insulin and Its Analogues
4.2.1 Rapid Acting Insulins
4.2.2 Short Acting Insulins
4.2.3 Intermediate Insulin
4.2.4 Long Lasting Insulins

Insulinotherapeutics in Diabetes
5.1 Conventional Insulinotherapy
5.2 Flexible or Intensive Insulinotherapy

Global Economic Aspects of Insulin
6.1 Skyrocketing Cost of Insulin Therapies
6.2 Emergence of Biosimilar

Global Economic Cost of Diabetes
7.1 Monetary Burden of Diabetes
7.2 US
7.3 Europe
7.4 Japan
7.5 China
7.6 India

Global Aspects of Biosimilar Insulins
8.1 US
8.2 Europe
8.3 Japan
8.4 Asia (Excluding Japan)

Global Biosimilar Insulin Market Overview
9.1 Preface to Biosimilar Insulin Market
9.2 Biosimilar Competition Assessment

Global Biosimilar Insulin Clinical Pipeline Insight

Marketed Biosimilar Insulin Clinical Insight by Company, Indication and Phase
11.1 Insulin Biosimilar (Wosulin-R)
11.2 Insulin Glargine Biosimilar (Glaritus, Glaritus Cart, Glaritus DispoPen)
11.3 Insulin Glargine Biosimilar (Abasaglar, Abasria and Basalgar)
11.4 Insulin Suspension Isophane/Insulin Biosimilar (Jusline 30/70)
11.5 Insulin Glargine Biosimilar (Basalog and GALACTUS)
11.6 Insulin Suspension Isophane Biosimilar (Jusline N)
11.7 Insulin Suspension Isophane/Insulin Biosimilar (Insulin H Mix)
11.8 Insulin Suspension Isophane Biosimilar (Insulin Hbio NPH)
11.9 Insulin Biosimilar (Insulin Hbio R)
11.10 Insulin Glargine Biosimilar (Basalin)
11.11 Insulin/Insulin Suspension Isophane Biosimilar (Wosulin 30/70, 50/50)
11.12 Insulin Suspension Isophane Biosimilar (Wosulin-N)
11.13 Insulin Biosimilar (Jusline R)
11.14 Insulin Glargine Biosimilar (Basugine)
11.15 Insulin Biosimilar (Insugen)

Biosimilar Insulin Future Targeted Market
12.1 Global High Prevalence of Diabetics
12.2 Global Prevalence of Obesity

Global Biosimilar Insulin Market Dynamics
13.1 Accelerating Parameters
13.2 Major Challenges of Biosimilar Insulin Market

Future Implications of Biosimilar Insulin

Competitive Landscape
15.1 Biocon
15.2 Biogenomics
15.3 Eli Lilly
15.4 GanandLee Pharmaceuticals
15.5 Geropharm
15.6 Julphar Gulf Pharmaceutical Industries
15.7 Paras Biopharmaceuticals
15.8 Samsung Bioepis
15.9 Sedico
15.10 Wockhardt

Download Report: https://www.kuickresearch.com/report-global-biosimilar-insulin-market-opportunity-and-clinical-insight-outlook-2022.php

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022 here

News-ID: 618565 • Views: 379

More Releases from Kuick Resarch

Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials In …
"Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" Report Highlights: o Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs o Marketed Cancer Antibody Drug Conjugate: 9 Drugs o Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026 o Majority of Drug Trials Are For Second Line Therapy Or Greater o USA Dominates Cancer ADC Clinical Trials Landscape: > 180 Drugs o Tubulin Modulators Dominates Cancer ADC Trials: > 60 Drugs o Sales, Market Opportunity, Clinical
Cancer Tumor Organoids Modelling Technology Market size Growth Assessment Person …
The research report "Global Cancer Tumor Organoids Modeling, Technology & Personalized Cancer Research Insight 2025" discusses about the recent trends and all the opportunities that the cancer organoid market have come across since the development of organoid technology in the research world. The research report delivers a comprehensive outlook about the transformation that the technique has brought in conducting cancer treatment as well as the transformation that the technique has
Global Transdermal Market Trends Demand Clinical Trials Pipeline Sales Opportuni …
The research report "Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" provides a comprehensive outlook about the wide applications that this delivery system in providing to the patients all over the globe. The research report also focuses towards introducing this delivery system and how it is contributing to relive the patients from the pain that the other drug delivery system provides in an elaborated way. In addition
Global Bispecific Antibodies Blincyto Hemlibra Market Sales Growth Clinical Tria …
The research report "Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026" provides a deep insight about the potential trends and the list of the drugs that are currently marketed under cancer bispecific antibodies. In addition to the general information, the research report also highlight the current scenario and various future prospects that the therapy is providing with respect to the growing cases of cancer at an

All 5 Releases


More Releases for Insulin

Insulin Patch Pumps Market Report 2018: Segmentation by Insulin Type (Bolus Insu …
Global Insulin Patch Pumps market research report provides company profile for Roche Holding AG, Cellnovo Group SA, Spring Health Solution Ltd., Debiotech, CeQur SA, Valeritas, Becton Dickenson & Company, Insulet Corporation, Johnson & Johnson, Medtrum Technologies Inc. and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue,
Insulin Delivery Devices Market - Insights
Insulin is vital for people suffering from type 1 diabetes and type 2 diabetes. In the past, patients with diabetes had to inject insulin using large glass syringes and reusable needles, both of which needed sterilization by boiling after each use. Improvements and innovations has led to development of insulin delivery devices such as pens and insulin pumps. Furthermore, insulin analogs have become available that enable both continuous subcutaneous insulin
Biosimilar Insulin Market Access
Boston, MA ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants
Global Insulin Delivery Machine Market: By Types - Insulin Pens, Insulin Pumps, …
Latest industry research report on: Global Insulin Delivery Machine Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Request For Sample Report @https://www.marketresearchreports.biz/sample/sample/1181480 This report studies Insulin Delivery Machine in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in
Global Insulin Pen Market Outlook 2016-2021
ReportBazzar has announced a new report titled “Global Insulin Pen Market Outlook 2016-2021” to their offerings. Browse report summery with TOC: http://www.reportbazzar.com/product/global-insulin-pen-market-outlook-2016-2021/ This report provides detailed analysis of worldwide markets for Insulin Pen from 2011-2016, and provides extensive market forecasts (2016-2021) by region/country and subsectors. It covers the key technological and market trends in the Insulin Pen market and further lays out an analysis of the factors influencing the supply/demand for Insulin Pen,